Biological and methodical challenges of blood-based proteomics in the field of neurological research

Progress in Neurobiology

Volumn 101-102, Issue 1, 2013, Pages 18-34

  Lista, Simone ^a   Faltraco, Frank ^a   Hampel, Harald ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Analytical bias; Plasma; Preanalytical bias; Proteomics; Serum

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTICOAGULANT AGENT; CITRATE SODIUM; CITRIC ACID; EDETIC ACID; HAPTOGLOBIN; HEPARIN; LIQUID NITROGEN; MACROGOL DERIVATIVE; POVIDONE; PREALBUMIN; PROTEINASE INHIBITOR; PROTEOME;

AGE; ALCOHOL CONSUMPTION; BIOINFORMATICS; BLOOD CLOTTING TIME; BLOOD SAMPLING; DIET; ENZYME ACTIVITY; ETHNICITY; EXERCISE; FRACTIONATION; FREEZE THAWING; FRUIT; GENDER; GENETIC POLYMORPHISM; HEMOCONCENTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; ISOELECTRIC FOCUSING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEUROLOGY; OBESITY; PHYSICAL ACTIVITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEOMICS; REVIEW; SMOKING; STANDARDIZATION; STORAGE TEMPERATURE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; ULTRAFILTRATION; VEGETABLE;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEOMICS; RESEARCH DESIGN;

EID: 84873155319     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.06.006     Document Type: Review

References (179)

1. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., Nixon R., Nutt J., Chung K., Zabetian C., Samii A., Lin M., Hattan S., Pan C., Wang Y., Jin J., Zhu D., Li G.J., Liu Y., Waichunas D., Montine T.J., Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Journal of Alzheimer's Disease 2006, 9:293-348.
2. Adkins J.N., Varnum S.M., Auberry K.J., Moore R.J., Angell N.H., Smith R.D., Springer D.L., Pounds J.G. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Molecular and Cellular Proteomics 2002, 1:947-955.
3. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
4. Ahmed N., Barker G., Oliva K.T., Hoffmann P., Riley C., Reeve S., Smith A.I., Kemp B.E., Quinn M.A., Rice G.E. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. British Journal of Cancer 2004, 91:129-140.
5. Albrethsen J., Bogebo R., Olsen J., Raskov H., Gammeltoft S. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum. Clinical Chemistry and Laboratory Medicine 2006, 44:1243-1252.
6. America A.H., Cordewener J.H., van Geffen M.H., Lommen A., Vissers J.P., Bino R.J., Hall R.D. Alignment and statistical difference analysis of complex peptide data sets generated by multidimensional LC-MS. Proteomic 2006, 6:641-653.
7. Anderson N.L., Anderson N.G. Microheterogeneity of serum transferrin, haptoglobin and alpha 2 HS glycoprotein examined by high resolution two-dimensional electrophoresis. Biochemical and Biophysical Research Communications 1979, 88:258-265.
8. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Molecular and Cellular Proteomics 2002, 1:845-867.
9. Anstey K.J., Cherbuin N., Budge M., Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obesity Reviews 2011, 12:e426-e437.
10. Apweiler R., Aslanidis C., Deufel T., Gerstner A., Hansen J., Hochstrasser D., Kellner R., Kubicek M., Lottspeich F., Maser E., Mewes H.W., Meyer H.E., Müllner S., Mutter W., Neumaier M., Nollau P., Nothwang H.G., Ponten F., Radbruch A., Reinert K., Rothe G., Stockinger H., Tarnok A., Taussig M.J., Thiel A., Thiery J., Ueffing M., Valet G., Vandekerckhove J., Verhuven W., Wagener C., Wagner O., Schmitz G. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clinical Chemistry and Laboratory Medicine 2009, 47:724-744.
11. Arnal N., Cristalli D.O., de Alaniz M.J., Marra C.A. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Research 2010, 1319:118-130.
12. Banks R.E., Stanley A.J., Cairns D.A., Barrett J.H., Clarke P., Thompson D., Selby P.J. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clinical Chemistry 2005, 51:1637-1649.
13. Barla A., Jurman G., Riccadonna S., Merler S., Chierici M., Furlanello C. Machine learning methods for predictive proteomics. Briefings in Bioinformatics 2008, 9:119-128.
14. Baudner S., Haupt H., Hubner R. Manufacture and characterization of a new reference preparation for 14 plasma proteins/CRM 470=RPPHS lot 5. Journal of Clinical Laboratory Analysis 1994, 8:177-190.
15. Baumann S., Ceglarek U., Fiedler G.M., Lembcke J., Leichtle A., Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clinical Chemistry 2005, 51:973-980.
16. Beck M., Claassen M., Aebersold R. Comprehensive proteomics. Current Opinion in Biotechnology 2011, 22:3-8.
17. Bergen H.R., Vasmatzis G., Cliby W.A., Johnson K.L., Oberg A.L., Muddiman D.C. Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Disease Markers 2003-2004, 19:239-249.
18. Beydoun M.A., Beydoun H.A., Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obesity Reviews 2008, 9:204-218.
19. Biron D.G., Brun C., Lefevre T., Lebarbenchon C., Loxdale H.D., Chevenet F., Brizard J.P., Thomas F. The pitfalls of proteomics experiments without the correct use of bioinformatics tools. Proteomics 2006, 6:5577-5596.
20. Björhall K., Miliotis T., Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005, 5:307-317.
21. Blirup-Jensen S., Johnson A.M., Larsen M. IFCC Committee on Plasma Proteins. Protein standardization V: value transfer. A practical protocol for the assignment of serum protein values from a Reference Material to a Target Material. Clinical Chemistry and Laboratory Medicine 2008, 46:1470-1479.
22. Bons J.A., de Boer D., van Dieijen-Visser M.P., Wodzig W.K. Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry. Clinica Chimica Acta 2006, 366:249-256.
23. Bons J.A., Wodzig W.K., van Dieijen-Visser M.P. Protein profiling as a diagnostic tool in clinical chemistry: a review. Clinical Chemistry and Laboratory Medicine 2005, 43:1281-1290.
24. Bortner J.D., Richie J.P., Das A., Liao J., Umstead T.M., Stanley A., Stanley B.A., Belani C.P., El-Bayoumy K. Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking. Journal of Proteomic Research 2011, 10:1151-1159.
25. Boschetti E., Lomas L., Citterio A., Righetti P.G. Romancing the hidden proteome, Anno Domini two zero zero seven. Journal of Chromatography A 2007, 1153:277-290.
26. Boschetti E., Righetti P.G. The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. Journal of Proteomics 2008, 71:255-264.
27. Bradshaw R.A., Burlingame A.L., Carr S., Aebersold R. Reporting protein identification data: the next generation of guidelines. Molecular and Cellular Proteomics 2006, 5:787-788.
28. Burtis C.A., Ashwood E. Tietz Fundamentals of Clinical Chemistry 2001, W.B. Saunders, Philadelphia, PA, USA.
29. Büttner J. The need for accuracy in laboratory medicine. European Journal of Clinical Chemistry and Clinical Biochemistry 1995, 33:981-988.
30. Callesen A.K., Mohammed S., Bunkenborg J., Kruse T.A., Cold S., Mogensen O., Christensen R., Vach W., Jørgensen P.E., Jensen O.N. Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Communications in Mass Spectrometry 2005, 19:1578-1586.
31. Cannataro M. Computational proteomics: management and analysis of proteomics data. Briefings in Bioinformatics 2008, 9:97-101.
32. Capila I., Linhardt R.J. Heparin-protein interactions. Angewandte Chemie International Edition in English 2002, 41:391-412.
33. Carrette O., Demalte I., Scherl A., Yalkinoglu O., Corthals G., Burkhard P., Hochstrasser D.F., Sanchez J.C. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3:1486-1494.
34. Castaño E.M., Roher A.E., Esh C.L., Kokjohn T.A., Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurology Research 2006, 28:155-163.
35. Chamrad D.C., Körting G., Stühler K., Meyer H.E., Klose J., Blüggel M. Evaluation of algorithms for protein identification from sequence databases using mass spectrometry data. Proteomics 2004, 4:619-628.
36. Cox J., Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annual Review of Biochemistry 2011, 80:273-299.
37. Cutler P., Akuffo E.L., Bodnar W.M., Briggs D.M., Davis J.B., Debouck C.M., Fox S.M., Gibson R.A., Gormley D.A., Holbrook J.D., Hunter A.J., Kinsey E.E., Prinjha R., Richardson J.C., Roses A.D., Smith M.A., Tsokanas N., Willé D.R., Wu W., Yates J.W., Gloger I.S. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clinical Applications 2008, 2:467-477.
38. Dammann C.E., Meyer M., Dammann O., von Neuhoff N. Protein detection in dried blood by surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF MS). Biology of the Neonate 2006, 89:126-132.
39. Davidsson P., Sjögren M., Andreasen N., Lindbjer M., Nilsson C.L., Westman-Brinkmalm A., Blennow K. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Research Molecular Brain Research 2002, 109:128-133.
40. De Bock M., de Seny D., Meuwis M.A., Chapelle J.P., Louis E., Malaise M., Merville M.P., Fillet M. Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. Journal of Biomedicine and Biotechnology 2010, 2010:906082.
41. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Molecular and Cellular Proteomics 2004, 3:367-378.
42. Domon B., Aebersold R. Mass spectrometry and protein analysis. Science 2006, 312:212-217.
43. Drabik A., Bierczynska-Krzysik A., Bodzon-Kulakowska A., Suder P., Kotlinska J., Silberring J. Proteomics in neurosciences. Mass Spectrometry Reviews 2007, 26:432-450.
44. Drake S.K., Bowen R.A., Remaley A.T., Hortin G.L. Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. Clinical Chemistry 2004, 50:2398-2401.
45. Echan L.A., Tang H.Y., Ali-Khan N., Lee K., Speicher D.W. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005, 5:3292-3303.
46. Ekegren T., Hanrieder J., Bergquist J. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research. Journal of Mass Spectrometry 2008, 43:559-571.
47. Engström G., Hedblad B., Stavenow L., Lind P., Janzon L., Lindgärde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003, 52:2097-2101.
48. Ezzelle J., Rodriguez-Chavez I.R., Darden J.M., Stirewalt M., Kunwar N., Hitchcock R., Walter T., D'Souza M.P. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. Journal of Pharmaceutical and Biomedical Analysis 2008, 7:18-29.
49. Fang X., Zhang W.W. Affinity separation and enrichment methods in proteomic analysis. Journal of Proteomics 2008, 71:284-303.
50. Ferguson R.E., Hochstrasser D.F., Banks R.E. Impact of preanalytical variables on the analysis of biological fluids in proteomic studies. Proteomics Clinical Applications 2007, 1:739-746.
51. Finehout E.J., Franck Z., Choe L.H., Relkin N., Lee K.H. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Annals of Neurology 2007, 61:120-129.
52. Forman M.S., Trojanowski J.Q., Lee V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nature Medicine 2004, 10:1055-1063.
53. Fu Q., Garnham C.P., Elliott S.T., Bovenkamp D.E., Van Eyk J.E. A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophoresis. Proteomics 2005, 5:2656-2664.
54. Gaspari M., Verhoeckx K.C., Verheij E.R., van der Greef J. Integration of two-dimensional LC-MS with multivariate statistics for comparative analysis of proteomic samples. Analytical Chemistry 2006, 78:2286-2296.
55. Gene Ontology Consortium, 2006. The Gene Ontology (GO) project in 2006. Nucleic Acids Research 34(Database issue), D322-D326.
56. Gillette M.A., Mani D.R., Carr S.A. Place of pattern in proteomic biomarker discovery. Journal of Proteome Research 2005, 4:1143-1154.
57. Good D.M., Thongboonkerd V., Novak J., Bascands J.L., Schanstra J.P., Coon J.J., Dominiczak A., Mischak H. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. Journal of Proteome Research 2007, 6:4549-4555.
58. Görg A., Weiss W., Dunn M.J. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4:3665-3685.
59. Govorukhina N.I., Reijmers T.H., Nyangoma S.O., van der Zee A.G., Jansen R.C., Bischoff R. Analysis of human serum by liquid chromatography-mass spectrometry: improved sample preparation and data analysis. Journal of Chromatography A 2006, 1120:142-150.
60. Granger C.B., Van Eyk J.E., Mockrin S.C., Anderson N.L. National Heart, Lung, And Blood Institute Clinical Proteomics Working Group. National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation 2004, 109:1697-1703.
61. Granger J., Siddiqui J., Copeland S., Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 2005, 5:4713-4718.
62. Gravel P., Walzer C., Aubry C., Balant L.P., Yersin B., Hochstrasser D.F., Guimon J. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. Biochemical and Biophysical Research Communications 1996, 220:78-85.
63. Grizzle W.E., Semmes O.J., Bigbee W., Zhu L., Malik G., Oelschlager D.K., Manne B., Manne U. The need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis. Cancer Information 2005, 1:86-97.
64. Guidi F., Magherini F., Gamberi T., Bini L., Puglia M., Marzocchini R., Ranaldi F., Modesti P.A., Gulisano M., Modesti A. Plasma protein carbonylation and physical exercise. Molecular BioSystems 2011, 7:640-650.
65. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology 1999, 17:994-999.
66. Haab B.B., Geierstanger B.H., Michailidis G., Vitzthum F., Forrester S., Okon R., Saviranta P., Brinker A., Sorette M., Perlee L., Suresh S., Drwal G., Adkins J.N., Omenn G.S. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005, 5:3278-3291.
67. Hermjakob H. The HUPO proteomics standards initiative-overcoming the fragmentation of proteomics data. Proteomics 2006, 6:34-38.
68. Hood B.L., Lucas D.A., Kim G., Chan K.C., Blonder J., Issaq H.J., Veenstra T.D., Conrads T.P., Pollet I., Karsan A. Quantitative analysis of the low molecular weight serum proteome using 18O stable isotope labeling in a lung tumor xenograft mouse model. Journal of the American Society for Mass Spectrometry 2005, 16:1221-1230.
69. Hsieh S.Y., Chen R.K., Pan Y.H., Lee H.L. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 2006, 6:3189-3198.
70. Hu Y., Hosseini A., Kauwe J.S., Gross J., Cairns N.J., Goate A.M., Fagan A.M., Townsend R.R., Holtzman D.M. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics Clinical Applications 2007, 1:1373-1384.
71. Hu Y., Malone J.P., Fagan A.M., Townsend R.R., Holtzman D.M. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Molecular and Cellular Proteomics 2005, 4:2000-2009.
72. Huang L., Harvie G., Feitelson J.S., Gramatikoff K., Herold D.A., Allen D.L., Amunngama R., Hagler R.A., Pisano M.R., Zhang W.W., Fang X. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 2005, 5:3314-3328.
73. Hutchens T.W., Yip T.T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Communications in Mass Spectrometry 1993, 7:576-580.
74. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
75. Issaq H.J., Veenstra T.D., Conrads T.P., Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochemical and Biophysical Research Communications 2002, 292:587-592.
76. Issaq H.J., Xiao Z., Veenstra T.D. Serum and plasma proteomics. Chemical Reviews 2007, 107:3601-3620.
77. Johnson A.M., Whicher J.T. Effect of certified reference material 470 (CRM 470) on national quality assurance programs for serum proteins in Europe. Clinical Chemistry and Laboratory Medicine 2001, 39:1123-1138.
78. Johnson K.L., Mason C.J., Muddiman D.C., Eckel J.E. Analysis of the low molecular weight fraction of serum by LC-dual ESI-FT-ICR mass spectrometry: precision of retention time, mass, and ion abundance. Analytical Chemistry 2004, 76:5097-5103.
79. Kaiser T., Wittke S., Just I., Krebs R., Bartel S., Fliser D., Mischak H., Weissinger E.M. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis 2004, 25:2044-2055.
80. Käll L., Vitek O. Computational mass spectrometry-based proteomics. PLoS Computational Biology 2011, 7:e1002277.
81. Kapp E.A., Schütz F., Connolly L.M., Chakel J.A., Meza J.E., Miller C.A., Fenyo D., Eng J.K., Adkins J.N., Omenn G.S., Simpson R.J. An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: sensitivity and specificity analysis. Proteomics 2005, 5:3475-3490.
82. Karas M., Hillenkamp F. Laser desorption ionization of proteins with molecular mass exceeding 10000 daltons. Analytical Chemistry 1988, 60:2299-2301.
83. Katajamaa M., Miettinen J., Oresic M. MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics 2006, 22:634-636.
84. Kim C.X., Bailey K.R., Klee G.G., Ellington A.A., Liu G., Mosley T.H., Rehman H., Kullo I.J. Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study. PLoS One 2010, 5:e9065.
85. Kim O.Y., Shin M.J., Moon J., Chung J.H. Plasma ceruloplasmin as a biomarker for obesity: a proteomic approach. Clinical Biochemistry 2011, 44:351-356.
86. Koomen J.M., Li D., Xiao L.C., Liu T.C., Coombes K.R., Abbruzzese J., Kobayashi R. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. Journal of Proteome Research 2005, 4:972-981.
87. Li H., Xie Z., Lin J., Song H., Wang Q., Wang K., Su M., Qiu Y., Zhao T., Song K., Wang X., Zhou M., Liu P., Zhao G., Zhang Q., Jia W. Transcriptomic and metabonomic profiling of obesity-prone and obesity-resistant rats under high fat diet. Journal of Proteome Research 2008, 7:4775-4783.
88. Liao P.C., Yu L., Kuo C.C., Lin C., Kuo Y.M. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics Clinical Applications 2007, 1:506-512.
89. Lippi G., Blanckaert N., Bonini P., Green S., Kitchen S., Palicka V., Vassault A.J., Plebani M. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clinical Chemistry and Laboratory Medicine 2008, 46:764-772.
90. Lippi G., Salvagno G.L., Brocco G., Guidi G.C. Preanalytical variability in laboratory testing: influence of the blood drawing technique. Clinical Chemistry and Laboratory Medicine 2005, 43:319-325.
91. Lippi G., Salvagno G.L., Montagnana M., Brocco G., Guidi G.C. Influence of hemolysis on routine clinical chemistry testing. Clinical Chemistry and Laboratory Medicine 2006, 44:311-316.
92. Lippi G., Salvagno G.L., Montagnana M., Poli G., Guidi G.C. Influence of the needle bore size on platelet count and routine coagulation testing. Blood Coagulation & Fibrinolysis 2006, 17:557-561.
93. Lopez M.F., Mikulskis A., Kuzdzal S., Bennett D.A., Kelly J., Golenko E., DiCesare J., Denoyer E., Patton W.F., Ediger R., Sapp L., Ziegert T., Lynch C., Kramer S., Whiteley G.R., Wall M.R., Mannion D.P., Della Cioppa G., Rakitan J.S., Wolfe G.M. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clinical Chemistry 2005, 51:1946-1954.
94. Luque-Garcia J.L., Neubert T.A. Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. Journal of Chromatography A 2007, 15:259-276.
95. Maccarrone G., Milfay D., Birg I., Rosenhagen M., Holsboer F., Grimm R., Bailey J., Zolotarjova N., Turck C.W. Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis 2004, 25:2402-2412.
96. Mann M., Hendrickson R.C., Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annual Review of Biochemistry 2001, 70:437-473.
97. Marshall J., Kupchak P., Zhu W., Yantha J., Vrees T., Furesz S., Jacks K., Smith C., Kireeva I., Zhang R., Takahashi M., Stanton E., Jackowski G. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. Journal of Proteome Research 2003, 2:361-372.
98. Merchant M., Weinberger S.R. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000, 21:1164-1177.
99. Merrell K., Southwick K., Graves S.W., Esplin M.S., Lewis N.E., Thulin C.D. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. Journal of Biomolecular Techniques 2004, 15:238-248.
100. Miike K., Aoki M., Yamashita R., Takegawa Y., Saya H., Miike T., Yamamura K. Proteome profiling reveals gender differences in the composition of human serum. Proteomics 2010, 10:2678-2691.
101. Miller I., Haynes P., Eberini I., Gemeiner M., Aebersold R., Gianazza E. Proteins of rat serum: III. Gender-related differences in protein concentration under baseline conditions and upon experimental inflammation as evaluated by two-dimensional electrophoresis. Electrophoresis 1999, 20:836-845.
102. Millioni R., Tolin S., Puricelli L., Sbrignadello S., Fadini G.P., Tessari P., Arrigoni G. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One 2011, 6:e19603.
103. Mischak H., Allmaier G., Apweiler R., Attwood T., Baumann M., Benigni A., Bennett S.E., Bischoff R., Bongcam-Rudloff E., Capasso G., Coon J.J., D'Haese P., Dominiczak A.F., Dakna M., Dihazi H., Ehrich J.H., Fernandez-Llama P., Fliser D., Frokiaer J., Garin J., Girolami M., Hancock W.S., Haubitz M., Hochstrasser D., Holman R.R., Ioannidis J.P., Jankowski J., Julian B.A., Klein J.B., Kolch W., Luider T., Massy Z., Mattes W.B., Molina F., Monsarrat B., Novak J., Peter K., Rossing P., Sánchez-Carbayo M., Schanstra J.P., Semmes O.J., Spasovski G., Theodorescu D., Thongboonkerd V., Vanholder R., Veenstra T.D., Weissinger E., Yamamoto T., Vlahou A. Recommendations for biomarker identification and qualification in clinical proteomics. Science Translational Medicine's 2010, 2. 46ps42.
104. Mischak H., Apweiler R., Banks R.E., Conaway M., Coon J., Dominiczak A., Ehrich J.H., Fliser D., Girolami M., Hermjakob H., Hochstrasser D., Jankowski J., Julian B.A., Kolch W., Massy Z.A., Neusuess C., Novak J., Peter K., Rossing K., Schanstra J., Semmes O.J., Theodorescu D., Thongboonkerd V., Weissinger E.M., Van Eyk J.E., Yamamoto T. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clinical Applications 2007, 1:148-156.
105. Mitchell B.L., Yasui Y., Lampe J.W., Gafken P.R., Lampe P.D. Evaluation of matrix-assisted laser desorption/ionization- time of flight mass spectrometry proteomic profiling: identification of alpha 2-HS glycoprotein B-chain as a biomarker of diet. Proteomics 2005, 5:2238-2246.
106. Mitchell B.L., Yasui Y., Li C.I., Fitzpatrick A.L., Lampe P.D. Impact of freeze-thaw cycles and storage time on plasma samples used in mass spectrometry based biomarker discovery projects. Cancer Information 2005, 1:98-104.
107. Nelsestuen G.L., Zhang Y., Martinez M.B., Key N.S., Jilma B., Verneris M., Sinaiko A., Kasthuri R.S. Plasma protein profiling: unique and stable features of individuals. Proteomics 2005, 5:4012-4024.
108. Nilsson C.L. Lectins: proteins that interpret the sugar code. Analytical Chemistry 2003, 75:348A-353A.
109. Nomura F., Tomonaga T., Sogawa K., Ohashi T., Nezu M., Sunaga M., Kondo N., Iyo M., Shimada H., Ochiai T. Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics 2004, 4:1187-1194.
110. O'Donovan C., Apweiler R., Bairoch A. The human proteomics initiative (HPI). Trends in Biotechnology 2001, 19:178-181.
111. Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., Apweiler R., Haab B.B., Simpson R.J., Eddes J.S., Kapp E.A., Moritz R.L., Chan D.W., Rai A.J., Admon A., Aebersold R., Eng J., Hancock W.S., Hefta S.A., Meyer H., Paik Y.K., Yoo J.S., Ping P., Pounds J., Adkins J., Qian X., Wang R., Wasinger V., Wu C.Y., Zhao X., Zeng R., Archakov A., Tsugita A., Beer I., Pandey A., Pisano M., Andrews P., Tammen H., Speicher D.W., Hanash S.M. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.
112. Orvisky E., Drake S.K., Martin B.M., Abdel-Hamid M., Ressom H.W., Varghese R.S., An Y., Saha D., Hortin G.L., Loffredo C.A., Goldman R. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics 2006, 6:2895-2902.
113. Palagi P.M., Hernandez P., Walther D., Appel R.D. Proteome informatics I: bioinformatics tools for processing experimental data. Proteomics 2006, 6:5435-5444.
114. Pan S., Zhu D., Quinn J.F., Peskind E.R., Montine T.J., Lin B., Goodlett D.R., Taylor G., Eng J., Zhang J. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 2007, 7:469-473.
115. Pappin D.J., Hojrup P., Bleasby A.J. Rapid identification of proteins by peptide-mass fingerprinting. Current Biology 1993, 3:327-332.
116. Patterson C., Feightner J., Garcia A., MacKnight C. General risk factors for dementia: a systematic evidence review. Alzheimers Dementia 2007, 3:341-347.
117. Pedrioli P.G., Eng J.K., Hubley R., Vogelzang M., Deutsch E.W., Raught B., Pratt B., Nilsson E., Angeletti R.H., Apweiler R., Cheung K., Costello C.E., Hermjakob H., Huang S., Julian R.K., Kapp E., McComb M.E., Oliver S.G., Omenn G., Paton N.W., Simpson R., Smith R., Taylor C.F., Zhu W., Aebersold R. A common open representation of mass spectrometry data and its application to proteomics research. Nature Biotechnology 2004, 22:1459-1466.
118. Pernemalm M., Lewensohn R., Lehtiö J. Affinity prefractionation for MS-based plasma proteomics. Proteomics 2009, 9:1420-1427.
119. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
120. Pieper R., Su Q., Gatlin C.L., Huang S.T., Anderson N.L., Steiner S. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003, 3:422-432.
121. Prados J., Kalousis A., Sanchez J.C., Allard L., Carrette O., Hilario M. Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents. Proteomics 2004, 4:2320-2332.
122. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Research Molecular Brain Research 2003, 118:140-146.
123. Rai A.J., Gelfand C.A., Haywood B.C., Warunek D.J., Yi J., Schuchard M.D., Mehigh R.J., Cockrill S.L., Scott G.B., Tammen H., Schulz-Knappe P., Speicher D.W., Vitzthum F., Haab B.B., Siest G., Chan D.W. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5:3262-3277.
124. Rai A.J., Stemmer P.M., Zhang Z., Adam B.L., Morgan W.T., Caffrey R.E., Podust V.N., Patel M., Lim L.Y., Shipulina N.V., Chan D.W., Semmes O.J., Leung H.C. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005, 5:3467-3474.
125. Ramström M., Hagman C., Mitchel l J.K., Derrick P.J., Håkansson P., Bergquist J. Depletion of high-abundant proteins in body fluids prior to liquid chromatography fourier transform ion cyclotron resonance mass spectrometry. Journal of Proteome Research 2005, 4:410-416.
126. Ramström M., Ivonin I., Johansson A., Askmark H., Markides K.E., Zubarev R., Håkansson P., Aquilonius S.M., Bergquist J. Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. Proteomics 2004, 4:4010-4018.
127. Ray S., Reddy P.J., Jain R., Gollapalli K., Moiyadi A., Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11:2139-2161.
128. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnology 2006, 24:971-983.
129. Righetti P.G., Boschetti E. Sherlock Holmes and the proteome - a detective story. FEBS Journal 2007, 274:897-905.
130. Righetti P.G., Boschetti E., Lomas L., Citterio A. Protein Equalizer Technology: the quest for a democratic proteome. Proteomics 2006, 6:3980-3992.
131. Rocke D.M. Design and analysis of experiments with high throughput biological assay data. Seminars in Cell & Developmental Biology 2004, 15:703-713.
132. Rüetschi U., Zetterberg H., Podust V.N., Gottfries J., Li S., Hviid Simonsen A., McGuire J., Karlsson M., Rymo L., Davies H., Minthon L., Blennow K. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Experimental Neurology 2005, 196:273-281.
133. Rusanen M., Kivipelto M., Quesenberry C.P., Zhou J., Whitmer R.A. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Archives of Internal Medicine 2011, 171:333-339.
134. Schuchard M.D., Mehigh R.J., Cockrill S.L., Lipscomb G.T., Stephan J.D., Wildsmith J., Valdes-Camin R., Kappel W.K., Rai A.J., Scott G.B. Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry. Biotechniques 2005, 39:239-247.
135. Schulte I., Tammen H., Selle H., Schulz-Knappe P. Peptides in body fluids and tissues as markers of disease. Expert Review of Molecular Diagnostics's 2005, 5:145-157.
136. Sennels L., Salek M., Lomas L., Boschetti E., Righetti P.G., Rappsilber J. Proteomic analysis of human blood serum using peptide library beads. Journal of Proteome Research 2007, 6:4055-4062.
137. Shen Y., Kim J., Strittmatter E.F., Jacobs J.M., Camp D.G., Fang R., Tolié N., Moore R.J., Smith R.D. Characterization of the human blood plasma proteome. Proteomics 2005, 5:4034-4045.
138. Sheta E.A., Appel S.H., Goldknopf I.L. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Review of Proteomics 2006, 3:45-62.
139. Simonsen A.H. Protein profiling of cerebrospinal fluid. Methods in Molecular Biology 2012, 818:109-117.
140. Simonsen A.H., McGuire J., Podust V.N., Davies H., Minthon L., Skoog I., Andreasen N., Wallin A., Waldemar G., Blennow K. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiology of Aging 2008, 29:961-968.
141. Smith F.M., Gallagher W.M., Fox E., Stephens R.B., Rexhepaj E., Petricoin E.F., Liotta L., Kennedy M.J., Reynolds J.V. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Annals of Surgery 2007, 245:259-266.
142. Spencer K. The influence of different sample collection types on the levels of markers used for Down's syndrome screening as measured by the Kryptor Immunosassay system. Annals of Clinical Biochemistry 2003, 40:166-168.
143. Stead D.A., Paton N.W., Missier P., Embury S.M., Hedeler C., Jin B., Brown A.J., Preece A. Information quality in proteomics. Briefings in Bioinformatics 2008, 9:174-188.
144. Steen G., Vermeer H.J., Naus A.J., Goevaerts B., Agricola P.T., Schoenmakers C.H. Multicenter evaluation of the interference of hemoglobin, bilirubin and lipids on Synchron LX-20 assays. Clinical Chemistry and Laboratory Medicine 2006, 44:413-419.
145. Steinmetz J., Tarallo P., Fournier B., Caces E., Siest Gl. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. European Journal of Clinical Chemistry and Clinical Biochemistry 1995, 33:337-342.
146. Stiles, T., Grant, V., Mawby, N., 2003. BARQA. Good Clinical Laboratory Practice (GCLP): A Quality System for Laboratories that undertake the Analyses of Samples from Clinical Trials.
147. Sweeney B., Proudfoot K., Parton A.H., King L.M., Slocombe P., Perry M.J. Purification of the T-cell receptor zeta-chain: covalent modification by 4-(2-aminoethyl)-benzenesulfonyl fluoride. Analytical Biochemistry 1997, 245:107-109.
148. Tambor V., Fucíková A., Lenco J., Kacerovský M., Rehácek V., Stulík J., Pudil R. Application of proteomics in biomarker discovery: a primer for the clinician. Physiological Research 2010, 59:471-497.
149. Tammen H. Specimen collection and handling: standardization of blood sample collection. Methods in Molecular Biology 2008, 428:35-42.
150. Tammen H., Schulte I., Hess R., Menzel C., Kellmann M., Mohring T., Schulz-Knappe P. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005, 5:3414-3422.
151. Taylor C.F., Hermjakob H., Julian R.K., Garavelli J.S., Aebersold R., Apweiler R. The work of the Human Proteome Organisation's Proteomics Standards Initiative (HUPO PSI). OMICS 2006, 10:145-151.
152. Taylor C.F., Paton N.W., Garwood K.L., Kirby P.D., Stead D.A., Yin Z., Deutsch E.W., Selway L., Walker J., Riba-Garcia I., Mohammed S., Deery M.J., Howard J.A., Dunkley T., Aebersold R., Kell D.B., Lilley K.S., Roepstorff P., Yates J.R., Brass A., Brown A.J., Cash P., Gaskell S.J., Hubbard S.J., Oliver S.G. A systematic approach to modeling, capturing, and disseminating proteomics experimental data. Nature Biotechnology 2003, 21:247-254.
153. Taylor C.F., Paton N.W., Lilley K.S., Binz P.A., Julian R.K., Jones A.R., Zhu W., Apweiler R., Aebersold R., Deutsch E.W., Dunn M.J., Heck A.J., Leitner A., Macht M., Mann M., Martens L., Neubert T.A., Patterson S.D., Ping P., Seymour S.L., Souda P., Tsugita A., Vandekerckhove J., Vondriska T.M., Whitelegge J.P., Wilkins M.R., Xenarios I., Yates J.R., Hermjakob H. The minimum information about a proteomics experiment (MIAPE). Nature Biotechnology 2007, 25:887-893.
154. Tewari A.K., Popova-Butler A., El-Mahdy M.A., Zweier J.L. Identification of differentially expressed proteins in blood plasma of control and cigarette smoke-exposed mice by 2-D DIGE/MS. Proteomics 2011, 11:2051-2062.
155. Thambisetty M., Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomarkers in Medicine 2010, 4:65-79.
156. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.O., Westman E., Kinsey A., Güntert A., Proitsi P., Powell J., Causevic M., Killick R., Lunnon K., Lynham S., Broadstock M., Choudhry F., Howlett D.R., Williams R.J., Sharp S.I., Mitchelmore C., Tunnard C., Leung R., Foy C., O'Brien D., Breen G., Furney S.J., Ward M., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Hodges A., Murphy D.G., Parkins S., Richardson J.C., Resnick S.M., Ferrucci L., Wong D.F., Zhou Y., Muehlboeck S., Evans A., Francis P.T., Spenger C., Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Archives of General Psychiatry 2010, 67:739-748.
157. Timms J.F., Arslan-Low E., Gentry-Maharaj A., Luo Z., T'Jampens D., Podust V.N., Ford J., Fung E.T., Gammerman A., Jacobs I., Menon U. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clinical Chemistry 2007, 53:645-656.
158. Tirumalai R.S., Chan K.C., Prieto D.A., Issaq H.J., Conrads T.P., Veenstra T.D. Characterization of the low molecular weight human serum proteome. Molecular and Cellular Proteomics 2003, 2:1096-1103.
159. Tracy R.P., Currie R.M., Young D.S. Two-dimensional gel electrophoresis of serum specimens from a normal population. Clinical Chemistry 1982, 28:890-899.
160. Tuck M.K., Chan D.W., Chia D., Godwin A.K., Grizzle W.E., Krueger K.E., Rom W., Sanda M., Sorbara L., Stass S., Wang W., Brenner D.E. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. Journal of Proteome Research 2009, 8:113-117.
161. Veltri P. Algorithms and tools for analysis and management of mass spectrometry data. Briefings in Bioinformatics 2008, 9:144-155.
162. Villanueva J., Martorella A.J., Lawlor K., Philip J., Fleisher M., Robbins R.J., Tempst P. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Molecular and Cellular Proteomics 2006, 5:1840-1852.
163. Villanueva J., Philip J., Chaparro C.A., Li Y., Toledo-Crow R., DeNoyer L., Fleisher M., Robbins R.J., Tempst P. Correcting common errors in identifying cancer-specific serum peptide signatures. Journal of Proteome Research 2005, 4:1060-1072.
164. Villanueva J., Philip J., Entenberg D., Chaparro C.A., Tanwar M.K., Holland E.C., Tempst P. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Analytical Chemistry 2004, 76:1560-1570.
165. Villar-Garea A., Griese M., Imhof A. Biomarker discovery from body fluids using mass spectrometry. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences 2007, 849:105-114.
166. Wagner M., Naik D., Pothen A. Protocols for disease classification from mass spectrometry data. Proteomics 2003, 3:1692-1698.
167. Wang Z., Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators of Inflammation 2010, 2010:535918.
168. Wenner B.R., Lovell M.A., Lynn B.C. Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. Journal of Proteome Research 2004, 3:97-103.
169. West-Nielsen M., Høgdall E.V., Marchiori E., Høgdall C.K., Schou C., Heegaard N.H. Sample handling for mass spectrometric proteomic investigations of human sera. Analytical Chemistry 2005, 77:5114-5123.
170. Wheeler D.L., Chappey C., Lash A.E., Leipe D.D., Madden T.L., Schuler G.D., Tatusova T.A., Rapp B.A. Database resources of the National Center for Biotechnology Information. Nucleic Acids Research 2000, 28:10-14.
171. Whicher J.T. Clin. Biochem. BCR/IFCC reference material for plasma proteins (CRM 470). Community Bureau of Reference. International Federation of Clinical Chemistry 1998, 31:459-465.
172. White J.G. EDTA-induced changes in platelet structure and function: clot retraction. Platelets 2000, 11:49-55.
173. Whiteaker J.R., Zhang H., Eng J.K., Fang R., Piening B.D., Feng L.C., Lorentzen T.D., Schoenherr R.M., Keane J.F., Holzman T., Fitzgibbon M., Lin C., Zhang H., Cooke K., Liu T., Camp D.G., Anderson L., Watts J., Smith R.D., McIntosh M.W., Paulovich A.G. Head-to-head comparison of serum fractionation techniques. Journal of Proteome Research 2007, 6:828-836.
174. Wilkins M.R., Appel R.D., Van Eyk J.E., Chung M.C., Görg A., Hecker M., Huber L.A., Langen H., Link A.J., Paik Y.K., Patterson S.D., Pennington S.R., Rabilloud T., Simpson R.J., Weiss W., Dunn M.J. Guidelines for the next 10 years of proteomics. Proteomics 2006, 6:4-8.
175. Zhang H., Liu A.Y., Loriaux P., Wollscheid B., Zhou Y., Watts J.D., Aebersold R. Mass spectrometric detection of tissue proteins in plasma. Molecular and Cellular Proteomics 2007, 6:64-71.
176. Zhang J., Goodlett D.R., Quinn J.F., Peskind E., Kaye J.A., Zhou Y., Pan C., Yi E., Eng J., Wang Q., Aebersold R.H., Montine T.J. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Journal of Alzheimer's Disease 2005, 7:125-133.
177. Zhang R., Barker L., Pinchev D., Marshall J., Rasamoelisolo M., Smith C., Kupchak P., Kireeva I., Ingratta L., Jackowski G. Mining biomarkers in human sera using proteomic tools. Proteomics 2004, 4:244-256.
178. Zolotarjova N., Martosella J., Nicol G., Bailey J., Boyes B.E., Barrett W.C. Differences among techniques for high-abundant protein depletion. Proteomics 2005, 5:3304-3313.
179. Zolotarjova N., Mrozinski P., Chen H., Martosella J. Combination of affinity depletion of abundant proteins and reversed-phase fractionation in proteomic analysis of human plasma/serum. Journal of Chromatography A 2008, 1189:332-338.